Table 1.
Baseline characteristics.
| Patients with of PV | Total N = 319 |
|---|---|
| Age at recruitment | 64.6 (11.8) |
| Sex (Males) | 198 (62.1) |
| Years from diagnosis to enrollment | 4.4 (5.5) |
| 0–2 | 146 (45.8) |
| 3–5 | 69 (21.6) |
| 6–10 | 64 (20.1) |
| >10 | 40 (12.5) |
|
| |
| Hematology | |
| Hb g/dL* | 15.2 (1.7) |
| HCT %* | 47.2 (4.6) |
| Platelets 10(6)/mm3 | 402 (184) |
| RBC 10(6)/mm3 | 5.7 (1.1) |
| WBC 10(3)/mm3 | 10.6 (14.9) |
|
| |
| Clinical chemistry | |
| Total cholesterol mg/dL | 173.1 (41.2) |
| HDL-cholesterol mg/dL | 47.7 (14.2) |
| LDL-cholesterol mg/dL | 99.2 (31.6) |
| Fasting blood glucose mg/dL | 94.1 (22.8) |
|
| |
| Prior cardiovascular events | |
| Prior thrombosis | 99 (31.2) |
| Arterial | 59 (18.6) |
| AMI | 27 (8.6) |
| Stroke | 10 (3.1) |
| TIA | 14 (4.4) |
| PAT | 2 (0.6) |
| Extremities | 5 (1.6) |
| Other | 2 (0.6) |
| Venous | 43 (13.6) |
| PE | 5 (1.6) |
| DVT | 21 (6.6) |
| SVT | 14 (4.4) |
| Other | 11 (3.5) |
| Arterial and venous | 4 (1.3) |
|
| |
| Prior haemorrhagic Events | 16 (5.1) |
| Major bleeding | 6 (1.9) |
| Brain | 1 (0.3) |
| Stroke | 0 (0.0) |
| GI | 4 (1.3) |
| Minor bleeding | 10 (3.1) |
| Erythromelalgia | 17 (5.4) |
|
| |
| Cardiovascular risk factors and comorbidity | |
| Hypertension | 175 (55.2) |
| Hypercholesterolemia | 55 (17.4) |
| Diabetes mellitus | 29 (9.2) |
| Current smoker | 32 (10.1) |
| Claudicatio intermittent | 2 (0.6) |
| Coronary arterial disease | 29 (9.1) |
|
| |
| Management of PV disease | |
| Phlebotomy | 261 (82.3) |
| AntiPLT | 266 (83.9) |
| Aspirin | 243 (76.7) |
| Anticoagulant | 41 (12.9) |
| Hydroxyurea | 167 (52.7) |
| 32P | 0 (0.0) |
| Busulphan | 2 (0.6) |
| Chorambucil | 0 (0.0) |
| Pipobroman | 14 (4.4) |
| Interferon | 7 (2.2) |
| JAK2 inhibitors | 0 (0.0) |
| Anagrelide | 0 (0.0) |
| Other cytoreductive drugs | 3 (1.0) |
|
| |
| Treatments for CV risk factors | |
| Hypocholesterolemic medication | 43 (13.6) |
| Anti diabetic medication | 16 (5.1) |
| Anti hypertensive medication | 153 (48.3) |
|
| |
| Cytogenetics | |
| Jak2 V617F (positive) | 307 (96.9) |
| Jak2 V617F (%) | 50.0 (27.6) |
| Jak2 V617F (negative) | 10 (3.2) |
| Jak2 Exon12 (positive) | 5 (1.6) |
| Jak2 Exon12 (negative) | 18 (5.7) |